Prof Helena Linardou speaks to ecancer at ELCC 2026 about her talk on the emerging role of bispecific immunotherapy in small cell lung cancer (SCLC).

She highlights the significant challenges associated with treating SCLC, including its aggressive nature and limited long-term treatment options, and explains how bispecific immunotherapies are being developed to overcome these barriers.

Prof Linardou outlines how bispecific antibodies differ from traditional immunotherapies, particularly in their ability to engage multiple targets simultaneously and enhance anti-tumour immune responses.

She also reviews the latest clinical evidence, discussing what current data reveal about their efficacy and safety profile.

Finally, she shares her perspective on where bispecific immunotherapy may fit within the future treatment landscape of SCLC and how it could potentially reshape patient outcomes.